Characterization of CD33/CD3 tetravalent bispecific tandem diabodies (TandAbs) for the treatment of acute myeloid leukemia

Clinical Cancer Research

Volumn 22, Issue 23, 2016, Pages 5829-5838

  Reusch, Uwe ^a   Harrington, Kimberly H ^b   Gudgeon, Chelsea J ^b   Fucek, Ivica ^a   Ellwanger, Kristina ^a   Weichel, Michael ^a   Knackmuss, Stefan H J ^a   Zhukovsky, Eugene A ^a   Fox, Judith A ^c   Kunkel, Lori A ^c   Guenot, Jeanmarie ^c   Walter, Roland B ^b,d  

^a Affimed GmbH   (Germany)

^b Fred Hutchinson Cancer Research Center   (United States)

^c Amphivena Therapeutics   (United States)

^d UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD3 ANTIBODY; CD3 ANTIGEN; CD33 ANTIBODY; CD33 ANTIGEN; MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG; AMINOGLYCOSIDE; BISPECIFIC ANTIBODY; CD33 PROTEIN, HUMAN; GEMTUZUMAB;

ACUTE MYELOBLASTIC LEUKEMIA; ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING AFFINITY; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER RECURRENCE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG POTENCY; FEMALE; HL 60 CELL LINE; HUMAN; HUMAN CELL; IN VITRO STUDY; LEUKEMIA CELL LINE; LYMPHOCYTE PROLIFERATION; MAJOR CLINICAL STUDY; MOUSE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; RECEPTOR DENSITY; T LYMPHOCYTE ACTIVATION; TUMOR CELL DESTRUCTION; TUMOR XENOGRAFT; ACUTE MYELOID LEUKEMIA; ANIMAL; BINDING SITE; HALF LIFE TIME; IMMUNOLOGY; IMMUNOTHERAPY; PROCEDURES; RANDOMIZED CONTROLLED TRIAL; T LYMPHOCYTE; TUMOR CELL LINE;

AMINOGLYCOSIDES; ANIMALS; ANTIBODIES, BISPECIFIC; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; BINDING SITES; CD3 COMPLEX; CELL LINE, TUMOR; HALF-LIFE; HUMANS; IMMUNOTHERAPY; LEUKEMIA, MYELOID, ACUTE; MICE; SIALIC ACID BINDING IG-LIKE LECTIN 3; T-LYMPHOCYTES;

EID: 85006325284     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-16-0350     Document Type: Article

References (33)

1. Walter RB, Appelbaum FR, Estey EH, Bernstein ID. Acute myeloid leukemia stem cells and CD33-targeted immunotherapy. Blood 2012;119:6198-208.
2. Laszlo GS, Estey EH, Walter RB. The past and future of CD33 as therapeutic target in acute myeloid leukemia. Blood Rev 2014;28:143-53.
3. Hills RK, Castaigne S, Appelbaum FR, Delaunay J, Petersdorf S, Othus M, et al. Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: ameta-analysis of individual patient data from randomised controlled trials. Lancet Oncol 2014;15: 986-96.
4. Gamis AS, Alonzo TA, Meshinchi S, Sung L, Gerbing RB, Raimondi SC, et al. Gemtuzumab ozogamicin in children and adolescents with de novo acute myeloid leukemia improves event-free survival by reducing relapse risk: results from the randomized phase III Children's Oncology Group trial AAML0531. J Clin Oncol 2014;32:3021-32.
5. Walter RB. Biting back: BiTE antibodies as a promising therapy for acute myeloid leukemia. Expert Rev Hematol 2014;7:317-9.
6. Carter P. Improving the efficacy of antibody-based cancer therapies. Nat Rev Cancer 2001;1:118-29.
7. Riethmüller G. Symmetry breaking: bispecific antibodies, the beginnings, and 50 years on. Cancer Immun 2012;12:12.
8. Stamova S, Cartellieri M, Feldmann A, Arndt C, Koristka S, Bartsch H, et al. Unexpected recombinations in single chain bispecific anti-CD3-anti-CD33 antibodies can be avoided by a novel linker module. Mol Immunol 2011;49:474-82.
9. Arndt C, von Bonin M, Cartellieri M, Feldmann A, Koristka S, Michalk I, et al. Redirection of T cells with a first fully humanized bispecific CD33-CD3 antibody efficiently eliminates AML blasts without harming hematopoietic stem cells. Leukemia 2013;27:964-7.
10. Arndt C, Feldmann A, von Bonin M, Cartellieri M, Ewen EM, Koristka S, et al. Costimulation improves the killing capability of T cells redirected to tumor cells expressing low levels of CD33: description of a novel modular targeting system. Leukemia 2014;28:59-69.
11. Aigner M, Feulner J, Schaffer S, Kischel R, Kufer P, Schneider K, et al. T lymphocytes can be effectively recruited for ex vivo and in vivo lysis of AML blasts by a novel CD33/CD3-bispecific BiTE antibody construct. Leukemia 2013;27:1107-15.
12. Krupka C, Kufer P, Kischel R, ZugmaierG, Bogeholz J, Kohnke T, et al.CD33 target validation and sustained depletion of AML blasts in long-term cultures by the bispecific T-cell-engaging antibody AMG 330. Blood 2014;123:356-65.
13. Laszlo GS, Gudgeon CJ, Harrington KH, Dell'Aringa J, Newhall KJ, Means GD, et al. Cellular determinants for preclinical activity of a novel CD33/CD3 bispecific T-cell engager (BiTE) antibody, AMG 330, against human AML. Blood 2014;123:554-61.
14. Friedrich M, Henn A, Raum T, Bajtus M, Matthes K, Hendrich L, et al. Preclinical characterization of AMG 330, a CD3/CD33-bispecific T-cellengaging antibody with potential for treatment of acute myelogenous leukemia. Mol Cancer Ther 2014;13:1549-57.
15. Krupka C, Kufer P, Kischel R, Zugmaier G, Lichtenegger FS, Kohnke T, et al. Blockade of the PD-1/PD-L1 axis augments lysis of AML cells by the CD33/CD3 BiTE antibody construct AMG 330: reversing a T-cell-induced immune escape mechanism. Leukemia 2016;30:484-91.
16. Laszlo GS,Gudgeon CJ, Harrington KH, Walter RB. T-cell ligands modulate the cytolytic activity of the CD33/CD3 BiTE antibody construct, AMG 330. Blood Cancer J 2015;5:e340.
17. Harrington KH, Gudgeon CJ, Laszlo GS, Newhall KJ, Sinclair AM, Frankel SR, et al. The broad anti-AML activity of the CD33/CD3 BiTE antibody construct, AMG 330, Is impacted by disease stage and risk. PLoS ONE 2015;10:e0135945.
18. Topp MS,Gökbuget N, Zugmaier G, Degenhard E,Goebeler ME, Klinger M, et al. Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL. Blood 2012;120:5185-7.
19. Topp MS, Gökbuget N, Zugmaier G, Klappers P, Stelljes M, Neumann S, et al. Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia. J Clin Oncol 2014; 32:4134-40.
20. Topp MS, Gökbuget N, Stein AS, Zugmaier G, O'Brien S, Bargou RC, et al. Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study. Lancet Oncol 2015;16:57-66.
21. Rothe A, Sasse S, Topp MS, Eichenauer DA, Hummel H, Reiners KS, et al. A phase 1 study of the bispecific anti-CD30/CD16A antibody construct AFM13 in patients with relapsed or refractory Hodgkin lymphoma. Blood 2015;125:4024-31.
22. McAleese F, Eser M. RECRUIT-TandAbs: harnessing the immune system to kill cancer cells. Future Oncol 2012;8:687-95.
23. Reusch U, Burkhardt C, Fucek I, Le Gall F, Le Gall M, Hoffmann K, et al. A novel tetravalent bispecific TandAb (CD30/CD16A) efficiently recruits NK cells for the lysis of CD30+ tumor cells. MAbs 2014;6:728-39.
24. Schwarz M, Röttgen P, Takada Y, Le Gall F, Knackmuss S, Bassler N, et al. Single-chain antibodies for the conformation-specific blockade of activated platelet integrin alphaIIbbeta3 designed by subtractive selection from naive human phage libraries. FASEB J 2004;18:1704-6.
25. Knackmuss S, Molkenthin V. Antibodies from IgM libraries. In: Little M, editor. Recombinant antibodies for immunotherapy. 1st ed.NewYork, NY: Cambridge University Press; 2009. p. 66-74.
26. Reusch U, Duell J, Ellwanger K, Herbrecht C, Knackmuss SH, Fucek I, et al. A tetravalent bispecific TandAb (CD19/CD3), AFM11, efficiently recruits T cells for the potent lysis of CD19(+) tumor cells. MAbs 2015;7:584-604.
27. Walter RB, Raden BW, Hong TC, Flowers DA, Bernstein ID, Linenberger ML. Multidrug resistance protein attenuates gemtuzumab ozogamicin-induced cytotoxicity in acute myeloid leukemia cells. Blood 2003;102:1466-73.
28. Walter RB, Raden BW, Kamikura DM, Cooper JA, Bernstein ID. Influence of CD33 expression levels and ITIM-dependent internalization on gemtuzumab ozogamicin-induced cytotoxicity. Blood 2005;105:1295-302.
29. Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 2009;114:937-51.
30. Grimwade D, Hills RK, Moorman AV, Walker H, Chatters S, Goldstone AH, et al. Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood 2010;116:354-65.
31. Portell CA, Wenzell CM, Advani AS. Clinical and pharmacologic aspects of blinatumomab in the treatment of B-cell acute lymphoblastic leukemia. Clin Pharmacol 2013;5:5-11.
32. Mager DE. Target-mediated drug disposition and dynamics. Biochem Pharmacol 2006;72:1-10.
33. Haas C, Krinner E, Brischwein K, Hoffmann P, Lutterbüse R, Schlereth B, et al. Mode of cytotoxic action of T cell-engaging BiTE antibody MT110. Immunobiology 2009;214:441-53.